UiPath Inc. (NYSE:PATH) CFO Ashim Gupta Sells 47,671 Shares

UiPath Inc. (NYSE:PATH) CFO Ashim Gupta sold 47,671 shares of the company’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $12.07, for a total transaction of $575,388.97. Following the transaction, the chief financial officer now owns 849,917 shares of the company’s stock, valued at $10,258,498.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

UiPath Stock Down 1.7 %

PATH stock traded down $0.21 during mid-day trading on Tuesday, hitting $12.27. 9,808,730 shares of the company were exchanged, compared to its average volume of 10,069,956. The business has a fifty day simple moving average of $12.11 and a 200-day simple moving average of $16.14. The firm has a market capitalization of $7.03 billion, a P/E ratio of -78.00 and a beta of 0.87. UiPath Inc. has a 12-month low of $10.37 and a 12-month high of $27.87.

UiPath (NYSE:PATH) last posted its earnings results on Thursday, September 5th. The healthcare company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.01. UiPath had a negative net margin of 8.13% and a negative return on equity of 3.98%. The firm had revenue of $316.00 million during the quarter, compared to the consensus estimate of $303.69 million. During the same quarter last year, the firm earned ($0.09) EPS. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. Research analysts predict that UiPath Inc. will post -0.23 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on PATH shares. KeyCorp restated a “sector weight” rating on shares of UiPath in a research report on Thursday, May 30th. Macquarie downgraded UiPath from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $29.00 to $12.00 in a research report on Monday, June 3rd. DA Davidson boosted their price target on UiPath from $13.00 to $15.00 and gave the stock a “neutral” rating in a research report on Friday, September 6th. BMO Capital Markets increased their price objective on UiPath from $14.00 to $15.00 and gave the company a “market perform” rating in a research note on Friday, September 6th. Finally, Scotiabank lowered their target price on shares of UiPath from $30.00 to $25.00 and set a “sector perform” rating on the stock in a research note on Wednesday, May 29th. Sixteen research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, UiPath has an average rating of “Hold” and an average target price of $17.71.

Institutional Investors Weigh In On UiPath

Several institutional investors and hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. increased its stake in UiPath by 23.7% during the 4th quarter. Russell Investments Group Ltd. now owns 38,584 shares of the healthcare company’s stock worth $958,000 after buying an additional 7,382 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of UiPath by 11.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,232,060 shares of the healthcare company’s stock valued at $55,454,000 after acquiring an additional 232,700 shares in the last quarter. Avantax Advisory Services Inc. boosted its holdings in UiPath by 7.1% in the fourth quarter. Avantax Advisory Services Inc. now owns 12,293 shares of the healthcare company’s stock valued at $305,000 after purchasing an additional 811 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in UiPath by 27.8% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 170,409 shares of the healthcare company’s stock worth $4,233,000 after purchasing an additional 37,103 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC increased its holdings in UiPath by 3.3% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 45,954 shares of the healthcare company’s stock worth $1,141,000 after purchasing an additional 1,458 shares during the period. Hedge funds and other institutional investors own 62.50% of the company’s stock.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.